References
- Klimo P. Chemotherapy for aggressive non-Hodgkin's lymphomas. Cancer: Principles and Practice of Oncology, Updates, V. T. DeVita, S. A. Rosenberg. Lippincott, Philadelphia 1988; 2: 1–12, (9)
- Coleman M. Chemotherapy for large-cell lymphoma: Optimism and caution (editorial). Ann Intern Med 1985; 103: 140–142
- Coleman M., Boyd D. B., Beshevkin M., . COP-BLAM treatment of large cell lymphoma: A status report. Update on Treatment for Diffuse Large Cell Lymphoma, A. T. Skarin, et al. Park Row, New York 1986; 63–69
- Coleman M., Armitage J. O., Gaynor M., et al. The COP-BLAM programs: Evolving chemotherapy concepts in large cell lymphomas. Semin Hematol 1988; 25(Suppl 2)23–33
- Coleman M., Boyd D. B., Bernhardt B., et al. COP-BLAM III: combination chemotherapy for diffuse large cell lymphoma with cyclophosphamide, infusional Oncovin, prednisone, infusional bleomycin, Adriamycin and Matulane (abstract). Proc Am Soc Clin Oncol 1984; 3: C-945
- Laurence J., Coleman M., Allen S. L., et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 1982; 97: 190–195
- American Joint Committee on Cancer. Hodgkin's and non-Hodgkin's lymphoma Manual for Staging of Cancer, 3rd ed, O. H. Beahrs, D. E. Henson, R. VP Hutter, M. H. Myers. Lippincott, Philadelphia 1988; 255–263
- Goldie J. H., Coldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
- Norton L., Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307–1317
- Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Dixon D. O., Neilan B., Jones S. E., et al. Effect of act on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305
- O'Connell M. J., Harrington D. P., Earle, et al. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma. J Clin Oncol 1987; 9: 1329–1339
- Gerhartz H. H., Thiel E., Hiller E., et al. CHOP and COPBLAM chemotherapy for diffuse large cell non-Hodgkin's lymphomas: a retrospective comparison. Hematol Oncol 1988; 6: 13–19
- Connors J. M., Klimo P. MACOP-B chemotherapy for malignant lymphoma and related conditions: 1987 update and additional observations. Semin Hematol 1988; 25(Suppl 2)41–46
- Vose J. M., Armitage J. O., Weisenburger D. D., et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989; 6: 1838–1844
- DeVita V. T., Hubbard S. M., Young R. C. The role of chemotherapy in diffuse aggressive lymphomas. Semin Hematol 1988; 25(Suppl 2)2–10
- Carlson R. W., Sikic B. I. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99: 823–833